2022-03-01 07:58:15 SNCE Science 37
03/01/22 03/0107:58 03/01/2207:58 | Science 37 publishes CNS therapeutic data from CNS surveyScience 37 Holdings published new CNS therapeutic data validating the growing trend toward decentralization as two-thirds of CNS survey respondents plan to execute an agile or decentralized clinical trial in 2022, an increase of more than 35 percent from last year. According to analysis, the CNS Research & Development spend will reach $32 billion USD by 2026, resulting in more than 4,000 clinical trials. To uncover these new trends in CNS clinical trials methodologies, Science 37 conducted a study of more than 70 clinical research executives, between December 2021 and January 2022. For CNS studies, survey respondents cited unexpected delays, data quality and limited patient populations among the key challenges for clinical trials, with effective patient recruitment as the single biggest challenge by more than 100% comparatively to the second challenge of endpoint collection. Being able to eliminate geographic barriers with agile and decentralized approaches and helping to ease patient burden can help alleviate these concerns and enable more efficient centralized enrollment into studies. The new data and insights also paint a vivid picture of the clinical trials landscape for the year ahead for CNS studies, suggesting significant increases in agile and decentralized approaches across numerous conditions-including major depressive disorder, Alzheimer's disease, and Parkinson's disease-and executed with a myriad of permutations of patient communities, mobile nursing, telemedicine investigators and connected devices - further demonstrating the need for a centralized Operating System with unified technology and centralized networks to effectively execute. Among the findings: Less than 60 percent of CNS respondents are planning to execute a traditional, site-based clinical trial in 2022, down from three in four for the previous year. Unexpected delays, data quality, and limited patient populations all ranked highly among the issues keeping respondents up at night, regarding CNS trials in general. Respondents cited the greatest single challenge of running an effective CNS study was patient recruitment by more than 100% comparatively to the second challenge of endpoint collection. Electronic clinical outcomes assessment and electronic patient-reported outcomes were cited as the most prevalent decentralized components in CNS, with two-thirds of CNS respondents planning to use these tools - showing the rising embrace of digital data collection and evidence generation. Among the largest-growing decentralized components of CNS studies cited were mobile nurses, up 40 percent and up 38 percent, respondents cited usage of Metasites or virtual sites that can enable more universal geographic coverage and access for patients. The three greatest perceived benefits of including agile and decentralized components in CNS clinical trials were increased patient retention, increased patient diversity and faster patient recruitment. |
|
---|
Recommendations
|
CytomX Therapeutics price target lowered to $3 from $9 at BMO Capital »
06:47 07/07/22 07/0706:47 07/07/2206:47
CTMX
CytomX Therapeutics
BMO Capital analyst Etzer… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Dillard's price target lowered to $150 from $215 at BofA »
06:47 07/07/22 07/0706:47 07/07/2206:47
DDS
Dillard's
BofA analyst Lorraine… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
KalVista reports Q4 EPS (98c), consensus ($1.09) »
06:46 07/07/22 07/0706:46 07/07/2206:46
KALV
KalVista
"We are pleased with… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
RBC downgrades Boston Beer with volumes not yet bottoming out »
06:46 07/07/22 07/0706:46 07/07/2206:46
SAM
Boston Beer
RBC Capital analyst Nik… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Nordstrom price target lowered to $15 from $21 at BofA »
06:46 07/07/22 07/0706:46 07/07/2206:46
JWN
Nordstrom
BofA analyst Lorraine… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Macy's price target lowered to $15 from $22 at BofA »
06:45 07/07/22 07/0706:45 07/07/2206:45
M
Macy's
BofA analyst Lorraine… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Argonaut Gold resumed with an Outperform rating at BMO Capital »
06:45 07/07/22 07/0706:45 07/07/2206:45
ARNGF
Argonaut Gold
BMO Capital analyst Brian… Story temporarily locked. ShowHide Related Items >><<
|
General news
| Energy Action: Oil prices… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
SoFi Technologies price target lowered to $7 from $9 at Mizuho »
06:43 07/07/22 07/0706:43 07/07/2206:43
SOFI
SoFi Technologies
Mizuho analyst Dan Dolev… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Citizens Financial price target lowered to $55 from $58 at RBC Capital »
06:43 07/07/22 07/0706:43 07/07/2206:43
CFG
Citizens Financial
RBC Capital analyst… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
T2 Biosystems downgraded to Neutral from Buy at BTIG »
06:43 07/07/22 07/0706:43 07/07/2206:43
TTOO
T2 Biosystems
BTIG analyst Mark Massaro… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
CytomX Therapeutics price target lowered to $8 from $16 at BTIG »
06:41 07/07/22 07/0706:41 07/07/2206:41
CTMX
CytomX Therapeutics
BTIG analyst Kaveri… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Entegris price target lowered to $146 from $160 at Mizuho »
06:41 07/07/22 07/0706:41 07/07/2206:41
ENTG
Entegris
CMC Materials
Mizuho analyst Kieran de… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Otis Worldwide downgraded to Neutral from Overweight at JPMorgan »
06:40 07/07/22 07/0706:40 07/07/2206:40
OTIS
Otis Worldwide
JPMorgan analyst Stephen… Story temporarily locked. ShowHide Related Items >><<
|
General news
| European Fixed Income… Story temporarily locked. ShowHide Related Items >><<
|
General news
| China eyes $220 B… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Kohl's downgraded to Underperform from Neutral at BofA »
06:39 07/07/22 07/0706:39 07/07/2206:39
KSS
Kohl's
BofA analyst Lorraine… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Charah Solutions awarded multi-year fly ash sales, marketing contract »
06:39 07/07/22 07/0706:39 07/07/2206:39
CHRA
Charah Solutions
Charah Solutions… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Element Solutions price target lowered to $26 from $29 at Mizuho »
06:38 07/07/22 07/0706:38 07/07/2206:38
ESI
Element Solutions
Mizuho analyst Kieran de… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Fisker announces Fisker Finance platform »
06:38 07/07/22 07/0706:38 07/07/2206:38
FSR
Fisker
Banco Santander
JPMorgan
Fisker announced Fisker… Story temporarily locked. ShowHide Related Items >><<
|
Recommendations
|
Air Products price target lowered to $286 from $312 at Mizuho »
06:37 07/07/22 07/0706:37 07/07/2206:37
APD
Air Products
Mizuho analyst… Story temporarily locked. ShowHide Related Items >><<
|
Downgrade
|
Bank OZK downgraded to Market Perform from Outperform at Raymond James »
06:36 07/07/22 07/0706:36 07/07/2206:36
OZK
Bank OZK
Raymond James analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Thor Industries' Vice President of Investor Relations Mark Trinske to retire »
06:36 07/07/22 07/0706:36 07/07/2206:36
THO
Thor Industries
Thor Industries announced… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Charah Solutions awarded multi-year contract for fly ash recycling in Indiana »
06:36 07/07/22 07/0706:36 07/07/2206:36
CHRA
Charah Solutions
Charah Solutions… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Immucell reports preliminary Q2 revenue $3.9M vs. $4.5M last year »
06:35 07/07/22 07/0706:35 07/07/2206:35
ICCC
Immucell
"A material… Story temporarily locked. ShowHide Related Items >><<
|